Literature DB >> 12545639

[Bilateral primary adrenal lymphoma].

Hanae Bakkali1, Hind el Omari-Alaoui, El Abbès Elghazi, Hassan Errihani, Nourredine Benjaafar, Brahim El Khalil Elgueddari.   

Abstract

The adrenal gland is a rare site of non-Hodgkin's lymphoma, as only about 70 cases have been reported in the literature, usually with bilateral involvement. Most tumours have a high grade histology, almost always with the B phenotype. Medical imaging is nonspecific and biopsy remains the most reliable diagnostic method. Chemotherapy is the treatment of choice, but the prognosis remains poor in the majority of cases, although long-term survivals have been described. The authors report a case of bilateral high-grade lymphoma of the adrenal glands in a 31-year-old patient presenting with acute adrenal insufficiency. Imaging demonstrated large bilateral adrenal masses, and surgical biopsy of the adrenal gland and staging confirmed the diagnosis of bilateral primary adrenal lymphoma. After corticosteroid replacement therapy, treatment consisted of primary CHOP chemotherapy administered for 9 cycles, followed by external beam radiotherapy delivered at a dose of 40 Gy. After 3 months of follow-up, the patient was still alive, with partial response, with an overall survival of 15 months.

Entities:  

Mesh:

Year:  2002        PMID: 12545639

Source DB:  PubMed          Journal:  Prog Urol        ISSN: 1166-7087            Impact factor:   0.915


  2 in total

1.  Vanishing adrenal mass.

Authors:  Anil Bhansali; B V Ajithkumar; Rama Walia; A Rajwanshi; G Shanmugasundar; Viral Shah
Journal:  BMJ Case Rep       Date:  2011-03-24

2.  The combination of early identification, chemotherapy, and autologous stem cell transplantation obtained favorable outcomes in unilateral primary adrenal lymphoma: A case report.

Authors:  Lu Huang; Xiao Shuai; Tingting Zhang; Pu Kuang; Dan Zhang; Tao Chen; Haoming Tian; Bing Xiang; Yan Ren
Journal:  Endocrine       Date:  2022-10-15       Impact factor: 3.925

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.